Document ID: chunk:federal_register_of_legislation:F2022C00913:reg:9:p2
Version: federal_register_of_legislation:F2022C00913
Segment Type: reg
Provision Reference: reg 9 (pt 2/3)
Character Range: 7509–10467

specified at the time of the clinical onset of deep vein thrombosis;
            Note: hypercoagulable state as specified is defined in the Schedule 1 - Dictionary.
(17)      having a kidney disease from the specified list of kidney diseases at the time of the clinical onset of deep vein thrombosis;
            Note: specified list of kidney diseases is defined in the Schedule 1 - Dictionary.
(18)      having a device implanted within the affected vein for a continuous period of at least 24 hours within the three months before the clinical onset of deep vein thrombosis;
            Note: Examples of implanted devices include a central venous catheter, an indwelling cardiac pacemaker and defibrillator leads.
(19)      having surgery requiring a general, spinal or epidural anaesthetic within the six months before the clinical onset of deep vein thrombosis;
(20)      having an injury or illness as specified within the three months before the clinical onset of deep vein thrombosis;
            Note: injury or illness as specified is defined in the Schedule 1 - Dictionary.
(21)      having restricted mobility for a continuous period of at least four hours within the four weeks before the clinical onset of deep vein thrombosis;
            Note: Examples of situations in which restricted mobility can occur include travel by road, rail or air and physical restraint.
(22)      having a neurological disease that causes loss or impairment of motor function of a limb within the three months before the clinical onset of deep vein thrombosis;
            Note: Examples of neurological diseases that cause loss or impairment of motor function of a limb include cerebrovascular accident, multiple sclerosis and motor neurone disease.
(23)      taking a drug from the specified list of drugs within the three months before the clinical onset of deep vein thrombosis;
            Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(24)      taking combined estrogen-progestogen contraception or taking menopausal hormone therapy as an oral estrogen, or a non-oral estrogen combined with a progestogen, for a continuous period of at least four weeks, within the three months before the clinical onset of deep vein thrombosis;
            Note: menopausal hormone therapy is defined in the Schedule 1 - Dictionary.
(25)      having smoked tobacco products:
(a)          in an amount of at least one pack-year before the clinical onset of deep vein thrombosis; or
(b)          in an amount of at least 10 cigarettes per day, or the equivalent thereof in other tobacco products, for a period of at least three months before the clinical onset of deep vein thrombosis; and
         if smoking has ceased before the clinical onset of deep vein thrombosis, then that onset occurred within six months of cessation;
            Note: cigarettes per day, or the equivalent thereof in other tobacco products and one pack-year are defined